FULC vs NTLA
FULC: Fulcrum Therapeutics discovers and develops treatments for genetically-defined rare diseases, with pociredir as a lead clinical-stage program. NTLA: CRISPR-based genome editing company developing in vivo therapies for rare genetic diseases including hereditary angioedema and ATTR amyloidosis.
Side-by-side fundamentals
| Metric | FULC | NTLA | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $3.70 | $11.13 | |
| Market cap as of 2026-07-23 | $248M | $1.6B | |
| PEG as of 2026-07-23 | -0.00 | n/a | |
| Net margin as of 2026-07-23 | +8.1% | -597.0% | FULC higher |
| Operating margin as of 2026-07-23 | -3.6% | -636.6% | FULC higher |
| ROE as of 2026-07-23 | -22.5% | -57.3% | FULC higher |
| ROA as of 2026-07-23 | -21.2% | -46.1% | FULC higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.00 | Tie |
| Revenue growth (YoY) as of 2026-07-23 | n/a | +45.0% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +9.1% | |
| Beta as of 2026-07-23 | 2.59 | 1.78 | |
| 1-year return as of 2026-07-22 close | -48.2% | -17.5% | NTLA higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.